Primary hyperaldosteronism differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 39: | Line 39: | ||
|+ | |+ | ||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnoses}} | ! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnoses}} | ||
! colspan=" | ! colspan="10" align="center" style="background:#4479BA; color: #FFFFFF; width: 400px;" + | Clinical features | ||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|History Findings}} | ! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|History Findings}} | ||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | ! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | ||
| Line 69: | Line 69: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | | ||
* Drug-resistant hypertension | * Drug-resistant hypertension | ||
| Line 88: | Line 87: | ||
|<nowiki>✔</nowiki> | |<nowiki>✔</nowiki> | ||
|<nowiki>✔</nowiki> | |<nowiki>✔</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| Line 121: | Line 119: | ||
|<nowiki>++</nowiki> | |<nowiki>++</nowiki> | ||
|<nowiki>+++</nowiki> | |<nowiki>+++</nowiki> | ||
| | | | ||
* [[Focal neurologic signs|Focal neurological signs]] present ([[motor neuron disease]]) | * [[Focal neurologic signs|Focal neurological signs]] present ([[motor neuron disease]]) | ||
| Line 155: | Line 152: | ||
|<nowiki>++</nowiki> | |<nowiki>++</nowiki> | ||
|<nowiki>+++</nowiki> | |<nowiki>+++</nowiki> | ||
| | | | ||
* [[Focal neurologic signs|Focal neurological signs]] present typically | * [[Focal neurologic signs|Focal neurological signs]] present typically | ||
| Line 176: | Line 172: | ||
** Diffuse post-ischemic lesions | ** Diffuse post-ischemic lesions | ||
|} | |} | ||
==References== | ==References== | ||
Revision as of 12:56, 16 October 2017
|
Primary hyperaldosteronism Microchapters |
|
Differentiating Primary Hyperaldosteronism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary hyperaldosteronism differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Primary hyperaldosteronism differential diagnosis |
|
Primary hyperaldosteronism differential diagnosis in the news |
|
Risk calculators and risk factors for Primary hyperaldosteronism differential diagnosis |
Overview
Primary hyperaldosteronism must be differentiated from other diseases that cause hypertension and hypokalemia such as renal artery stenosis, cushing's syndrome, congenital adrenal hyperplasia, Liddle's syndrome, diuretic use, licorice ingestion and renin-secreting tumors.
Differentiating Primary Hyperaldosteronism from other Diseases
Primary hyperaldosteronism (PA) should be differentiated from other diseases causing hypertension and hypokalemia for example:[1][1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]
- Renal artery stenosis
- Cushing's syndrome
- Congenital adrenal hyperplasia (CAH)
- Liddle's syndrome
- Diuretic use
- Licorice ingestion
- Renin-secreting tumors
| Hypertension and Hypokalemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plasma renin activity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Normal or High (Plasma Renin/Aldosterone ratio <10 | Suppressed (Plasma Renin/Aldosterone ratio >20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| *Renin-secreting tumors *Diuretic use *Renovascular hypertension *Coarctation of aorta *Malignant phase hypertension | Urinary aldosterone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Elevated | Normal | Low | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conn's syndrome (Primary aldosteronism) | Profound K+ depletion | • 17 alpha hydroxylase deficiency • 11 beta hydroxylase deficiency • Liddle's syndrome • Licorice ingestion • Deoxycortisone producing tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Add Mineralocrticoid antagonist for 8 weeks | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BP response | No BP response | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| • Deoxycorticosterone excess( Tumor, 17 alpha hydroxylase and 11 beta hydroxylase deficiency) • Licorice ingestion •Glucocorticoid resistance | Liddle's syndrome) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Differential Diagnoses | Clinical features | History Findings | Laboratory Findings | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Nausea | Vomiting | Palpitations | Shortness of breath | Diminished pulses | Fatigue | Constipation | Visual Abnormalities | Pruritis | Polyuria | |||
| Renin-Secreting tumors | ✔
(Due to hypertension) |
✔ | ✔ | ✔ | - | - | - | - | - | - |
|
| |
| Coarctation of aorta | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | - | - | - |
|
| |
| Frontotemporal lobar degeneration | +/- | - | Helpful | +++ | + | - | +++ | +++ | ++ | +++ |
|
|
|
| Vascular dementia | + (Dysexecutive syndrome) | - | Helpful | + | + | + | ++ | - | ++ | +++ |
|
|
|
References
- ↑ 1.0 1.1 Wada N, Jin S, Hui SP, Yanagisawa K, Kurosawa T, Chiba H (2014). "[Differential diagnosis of primary aldosteronism by measurement of hybrid steroids using mass spectrometry]". Rinsho Byori (in Japanese). 62 (3): 276–82. PMID 24800505.
- ↑ Nielsen ML, Pareek M, Andersen I (2012). "[Liquorice-induced hypertension and hypokalaemia]". Ugeskr. Laeg. (in Danish). 174 (15): 1024–5. PMID 22487411.
- ↑ Chow KM, Ma RC, Szeto CC, Li PK (2012). "Polycystic kidney disease presenting with hypertension and hypokalemia". Am. J. Kidney Dis. 59 (2): 270–2. doi:10.1053/j.ajkd.2011.08.020. PMID 21962616.
- ↑ Sarafidis PA, Georgianos PI, Germanidis G, Giavroglou C, Nikolaidis P, Lasaridis AN, Madias NE (2012). "Hypertension and symptomatic hypokalemia in a patient with simultaneous unilateral stenoses of intrarenal arteries and mesangioproliferative glomerulonephritis". Am. J. Kidney Dis. 59 (3): 434–8. doi:10.1053/j.ajkd.2011.11.001. PMID 22154539.
- ↑ Khosla N, Hogan D (2006). "Mineralocorticoid hypertension and hypokalemia". Semin. Nephrol. 26 (6): 434–40. doi:10.1016/j.semnephrol.2006.10.004. PMID 17275580.
- ↑ Weiner ID (2013). "Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism". Semin. Nephrol. 33 (3): 265–76. doi:10.1016/j.semnephrol.2013.04.007. PMC 3748390. PMID 23953804.
- ↑ Martell-Claros N, Abad-Cardiel M, Alvarez-Alvarez B, García-Donaire JA, Pérez CF (2015). "Primary aldosteronism and its various clinical scenarios". J. Hypertens. 33 (6): 1226–32. doi:10.1097/HJH.0000000000000546. PMID 25715092.
- ↑ Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB (2000). "Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program". Hypertension. 35 (5): 1025–30. PMID 10818057.
- ↑ Rossi E, Farnetti E, Nicoli D, Sazzini M, Perazzoli F, Regolisti G, Grasselli C, Santi R, Negro A, Mazzeo V, Mantero F, Luiselli D, Casali B (2011). "A clinical phenotype mimicking essential hypertension in a newly discovered family with Liddle's syndrome". Am. J. Hypertens. 24 (8): 930–5. doi:10.1038/ajh.2011.76. PMID 21525970.
- ↑ Ruecker B, Lang-Muritano M, Spanaus K, Welzel M, l'Allemand D, Phan-Hug F, Katschnig C, Konrad D, Holterhus PM, Schoenle EJ (2015). "The Aldosterone/Renin Ratio as a Diagnostic Tool for the Diagnosis of Primary Hypoaldosteronism in Newborns and Infants". Horm Res Paediatr. 84 (1): 43–8. doi:10.1159/000381852. PMID 25968592.
- ↑ Ardhanari S, Kannuswamy R, Chaudhary K, Lockette W, Whaley-Connell A (2015). "Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension". Adv Chronic Kidney Dis. 22 (3): 185–95. doi:10.1053/j.ackd.2015.03.002. PMID 25908467.
- ↑ Iglesias P, Tajada P, Martínez I, Díez JJ (2009). "[Salt-wasting congenital adrenal hyperplasia associated to hyperreninemic hyperaldosteronism]". Med Clin (Barc) (in Spanish; Castilian). 132 (2): 80–1. doi:10.1016/j.medcli.2008.09.002. PMID 19174076.
- ↑ Kikuta Y, Sanjo K, Nakajima K, Ashizawa I, Ojima M (1988). "Primary aldosteronism in childhood due to primary adrenal hyperplasia". Tohoku J. Exp. Med. 155 (1): 57–70. PMID 3413779.
- ↑ Hassan-Smith Z, Stewart PM (2011). "Inherited forms of mineralocorticoid hypertension". Curr Opin Endocrinol Diabetes Obes. 18 (3): 177–85. doi:10.1097/MED.0b013e3283469444. PMID 21494136.
- ↑ Bartter FC, Henkin RI, Bryan GT (1968). "Aldosterone hypersecretion in "non-salt-losing" congenital adrenal hyperplasia". J. Clin. Invest. 47 (8): 1742–52. doi:10.1172/JCI105864. PMC 297334. PMID 4299011.